Michael Yee
Stock Analyst at Jefferies
(2.86)
# 1,775
Out of 4,969 analysts
78
Total ratings
39.62%
Success rate
10.9%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.96 | +211.85% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $8.57 | +133.51% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $141.62 | +27.10% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $396.60 | +38.68% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $283.85 | +33.87% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $15.31 | +193.93% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $24.05 | +128.69% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $14.62 | +139.40% | 1 | Oct 8, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $40 | $15.39 | +159.91% | 1 | Sep 13, 2024 | |
| AXON Axon Enterprise | Initiates: Buy | $385 | $725.29 | -46.92% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $3.15 | +217.46% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $5.36 | -44.03% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $18.76 | +59.91% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.02 | +33.16% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $34.40 | -41.86% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $10.64 | +604.89% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $2.59 | +1,058.30% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $35.29 | +84.19% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $12.10 | +9,197.52% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $2.44 | +1,132.03% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $8.39 | +257.78% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $23.76 | +405.05% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $19.29 | +288.80% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $27.92 | +7.45% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $19.36 | +297.73% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $112.99 | - | 3 | Jan 26, 2018 |
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.96
Upside: +211.85%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $8.57
Upside: +133.51%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $141.62
Upside: +27.10%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $396.60
Upside: +38.68%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $283.85
Upside: +33.87%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $15.31
Upside: +193.93%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $24.05
Upside: +128.69%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $14.62
Upside: +139.40%
Oruka Therapeutics
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $15.39
Upside: +159.91%
Axon Enterprise
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $725.29
Upside: -46.92%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $3.15
Upside: +217.46%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $5.36
Upside: -44.03%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $18.76
Upside: +59.91%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.02
Upside: +33.16%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $34.40
Upside: -41.86%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $10.64
Upside: +604.89%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $2.59
Upside: +1,058.30%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $35.29
Upside: +84.19%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $12.10
Upside: +9,197.52%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $2.44
Upside: +1,132.03%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $8.39
Upside: +257.78%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $23.76
Upside: +405.05%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $19.29
Upside: +288.80%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $27.92
Upside: +7.45%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $19.36
Upside: +297.73%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $112.99
Upside: -